Find in Library

Objective:We aimed to evaluate the effects of leuprolide 22.5 mg and goserelin 10.8 mg on castration levels in patients with metastatic prostate cancer.Method:We evaluated 50 metastatic prostate cancer patients between 01.06.2012-01.06.2014, retrospectively. Of the patients, 25 received leuprolide 22.5 mg and 25 received goserelin 10.8 mg. Patients were followed up for 2 years and testosterone, prostate specific antigen (PSA) values were checked in every 3-months periods.Results:The mean age of the patients were 64.48±8.18 and 65.52±7.93 years in leuprolide 22.5 mg and goserelin 10.8 mg groups, respectively (p=0.466). The mean Gleason score of the patients in both groups were similar (7.80±0.95 vs 7.84±1.17, p=0.949). Two (8%) patients treated with leuprolide and three (12%) patients treated with goserelin had testosterone levels above castration during follow-up. There were no statistically significant differences between the two groups in terms of reaching castration levels (p=0.641). There were no statistically significant differences between the drugs in the duration of exceeding from the castration levels (16.5 months vs. 13 months, p=0.4). In both groups, patients with low Gleason score (<9), single organ metastasis at the time of diagnosis, and PSA values of 2.5 ng/mL and below remained castrated for a longer period of time.Conclusion:Both leuprolide 22.5 mg and goserelin 10.8 mg are effective in achieving castration levels among metastatic prostate cancer patients. However, patients with low Gleason score (<9), single organ metastasis at the time of diagnosis and PSA values of 2.5 ng/mL and below remained castrated for a longer period of time.